Table 3.
The adjusted odds ratio (95% confidence interval) describing the annual variation in susceptibility of Actinobacillus pleuropneumoniae (APP) isolates to quinolones (enrofloxacin and marbofloxacin), tetracyclines (doxycycline and oxytetracycline), beta-lactams (ceftiofur and amoxicillin), phenicols (florfenicol), sulfonamides (sulfamethoxazol/trimethoprim), pleuromutilins (tiamulin) and macrolides (tilmicosin, tulathromycin and tildipirosin) using the logistic regression model
| Drug | Enrofloxacin | Marbofloxacin | Doxycycline | Oxytetracycline |
|---|---|---|---|---|
| Year | S (P = 0.0002) | S (P < 0.0001) | S (p < 0.0001) | S (p = 0.008) |
| 20 vs. 19 | S- 2.7 (1.6–4.8) | S- 2.6 (1.5–4.6) | S- 0.5 (0.29–0.84) | T (p = 0.09) |
| 21 vs. 20 | NS | NS | S- 0.4 (0.22–0.71) | T (p = 0.07) |
| 22 vs. 21 | NS | NS | NS | S- 1.69 (1.10–2.71) |
| Drug | Ceftiofur | Amoxicillin | Florfenicol | Sulfamethoxazol/trimethoprim |
| Year | NS | S (p = 0.01) | NS | NS |
| 20 vs. 19 | NS | NS | NS | NS |
| 21 vs. 20 | NS | NS | NS | NS |
| 22 vs. 21 | NS | S- 1.79 (1.21–2.67) | NS | NS |
| Drug | Tiamulin | Tilmicosin | Tulathromycin | Tildipirosin |
| Year | S (p < 0.0001) | S (p < 0.0001) | NS | NS |
| 20 vs. 19 | S- 0.06 (0.008–0.46) | S- 0.06 (0.008–0.49) | NS | NS |
| 21 vs. 20 | S- 7.75 (2.63–22.8) | S- 4.16 (1.73–9.96) | NS | NS |
| 22 vs. 21 | NS | S- 0.28 (0.12–0.68) | NS | NS |
S means significant (p < 0.05). OR is significant if the confidence interval 95% does not contain the 1 value
NS means not significant (p > 0.05)
T means statistical tendency